All In Biotech

Drug Trial Radar · NCT01482156

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Jan 2012

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 30, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study has two parts: 1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in patients with advanced solid tumors. 2. Dose-expansion: to assess safety and tolerability of RAD001 and BEZ235 at the MTD in patients with ER+/HER2- metastatic breast cancer and metastatic renal cell cancer

Conditions

  • Advanced Solid Tumors
  • Metastatic Breast Cancer
  • Metastatic Renal Cell Carcinoma

Interventions

  • RAD001 + BEZ235Drug

    RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Probability of a Dose Limiting Toxicity (DLT) by the end of the first treatment cycle (DLT)Time frame: First treatment cycle (28 days)
  2. Incidence of DLT in patients by the end of the first treatment cycle in the co-administration of RAD001 and BEZ235Time frame: First treatment cycle (28 days)
  3. Number of participants with adverse events and serious adverse events.Time frame: 12 months

Locations

10 sites in 7 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group Dept of Highlands Oncology Grp

    Fayetteville, Arkansas

  • Washington University School of Medicine Washington University (16)

    St Louis, Missouri

  • Medical University of South Carolina SC

    Charleston, South Carolina

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Montellier Cedex 5, France

  • Novartis Investigative Site

    Verona, VR, Italy

  • Novartis Investigative Site

    Auckland, New Zealand

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    High Heaton, Newcastle Upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.